Stratagene Directors Receive Options to Buy 200,000 Shares; Stock Hits 52-Week Low | GenomeWeb

Several Stratagene directors and executive managers recently received options to purchase roughly 200,000 shares of the firm's stock amid a precipitous decline in the stock's price, though the two events are unrelated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.